The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
 
JUNG-YUN LEE
Consulting or Advisory Role - AstraZeneca; MSD; Roche; Takeda
Research Funding - Ascendis Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Janssen Oncology (Inst); Merck (Inst); Mersana (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); OncoQuest Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); Synthon (Inst); Takeda (Inst)
 
Junsik Park
No Relationships to Disclose
 
Chel Hun Choi
No Relationships to Disclose
 
Hyun Woong Cho
No Relationships to Disclose
 
Jae Hong No
No Relationships to Disclose
 
Dae Gy Hong
No Relationships to Disclose